Welcome to our dedicated page for Fulgent Genetics news (Ticker: FLGT), a resource for investors and traders seeking the latest updates and insights on Fulgent Genetics stock.
Fulgent Genetics, Inc. (NASDAQ: FLGT) regularly issues news and updates that reflect its dual focus on laboratory services and oncology therapeutic development. Company press releases cover topics such as quarterly and annual financial results, clinical trial progress for its cancer drug candidates, regulatory milestones for its genomic testing platforms, and strategic transactions in the laboratory and pathology space. Because Fulgent describes itself as a technology-based company with ambitions in precision medicine, its news flow often highlights both operational performance and advances in its technology and therapeutic pipelines.
Investors following FLGT news can expect detailed earnings releases that discuss revenue, core revenue, GAAP and non-GAAP results, gross margins, and adjusted EBITDA, along with commentary from management on business trends in the laboratory services and therapeutic development segments. The company also announces the timing of upcoming earnings calls and investor conference presentations through news releases, providing context for when management will discuss the business with the investment community.
Beyond financial reporting, Fulgent’s news includes updates on its oncology programs, such as preliminary clinical data from trials of FID-007 in recurrent or metastatic head and neck squamous cell carcinoma. The company also reports on regulatory achievements, including CE certification in the European Union for its FulgentExome and Fulgent Pipeline Manager (PLM) germline next-generation sequencing system. In addition, Fulgent uses press releases to announce strategic moves in laboratory and pathology services, such as its agreement to acquire selected assets of Bako Diagnostics and to acquire StrataDx.
This FLGT news page aggregates these types of announcements so readers can review financial disclosures, clinical development updates, technology milestones, and transaction-related news in one place. For those tracking Fulgent’s progress toward its stated goal of becoming a fully integrated precision medicine company, the news feed provides an ongoing view of how the company reports its operational and strategic developments.
Fulgent Genetics (NASDAQ: FLGT) will release its third quarter 2025 financial results before the market opens on Friday, November 7, 2025. Management will host a conference call the same day at 8:30 AM ET (5:30 AM PT) to discuss results and answer investor questions.
The call is accessible via a live audio webcast on the company Investor Relations site at http://ir.fulgentgenetics.com, and an audio replay will be available at the same location.
Fulgent Genetics (NASDAQ: FLGT) reported its Q2 2025 financial results, with core revenue growing 16% year-over-year to $81.7 million. The company posted a GAAP loss of $19.0 million (($0.62) per share) but achieved non-GAAP income of $2.1 million ($0.07 per share).
Key highlights include a strong cash position of $777.5 million in cash and investments, continued share repurchases of approximately 130,000 shares at $2.2 million, and raised full-year 2025 guidance to $320 million in core revenue. The company maintained solid gross margins with GAAP gross margin of 42.1% and non-GAAP gross margin of 44.2%.
Management expressed confidence in the company's growth trajectory, citing progress in both Laboratory Services and Therapeutic Development businesses.
Fulgent Genetics (NASDAQ: FLGT) has achieved CE certification under the EU's In Vitro Diagnostic Regulation for its germline next-generation sequencing system, including FulgentExome and Fulgent Pipeline Manager (PLM). The company may be the first laboratory to receive CE mark for such a comprehensive end-to-end germline testing offering, validating over 4,600 genes for diagnostic use.
FulgentExome is designed to examine coding regions and splice junctions, focusing on clinically relevant variants to aid in diagnosing suspected genetic conditions. The Fulgent PLM software works within the FulgentExome system to analyze genetic sequencing data. This certification enables Fulgent to expand its services throughout Europe and potentially support clinical trials and reimbursement pathways under IVDR.
Fulgent Genetics (NASDAQ: FLGT), a technology company specializing in laboratory services and therapeutic development, has scheduled its second quarter 2025 financial results announcement for Friday, August 1, 2025, before market opening.
The company will host an investor conference call at 8:30 AM ET (5:30 AM PT) on the same day. Investors can access the live audio webcast through the Investor Relations section of Fulgent's website, with an audio replay available afterward.
Fulgent Genetics (NASDAQ: FLGT), a technology-based company operating in laboratory services and therapeutic development, has scheduled its first quarter 2025 financial results announcement for Friday, May 2, 2025, before market opening.
The company will host an investment community conference call at 8:30 AM ET (5:30 AM PT) on the same day. Management will present the results and conduct a Q&A session. Investors can access the live audio webcast through the Investor Relations section of Fulgent's website, with an audio replay available afterward.
Fulgent Genetics (NASDAQ: FLGT) has reported its financial results for Q4 and full year 2024. The company achieved total revenue of $283.5 million for the full year, with core revenue growing 7% year-over-year to $281.2 million.
Key financial highlights include:
- Q4 total revenue of $76.2 million with core revenue up 14% year-over-year to $76.0 million
- Full year GAAP loss of $42.7 million, or ($1.41) per share
- Non-GAAP income of $15.0 million, or $0.49 per share
- Strong cash position of $828.6 million ($26.87 per share)
For 2025, Fulgent projects core revenue of approximately $310 million, with an expected GAAP loss of ($1.95) per share and non-GAAP loss of ($0.65) per share. The company anticipates ending 2025 with approximately $780 million in cash and investments.
Fulgent Genetics (NASDAQ: FLGT) has announced it will release its fourth quarter and full year 2024 financial results before market opens on Friday, February 28, 2025. The company will host a conference call for investors at 8:30 AM ET (5:30 AM PT) on the same day, where management will discuss results and answer questions. The call will be accessible through a live audio webcast on the Investor Relations section of Fulgent's website, with an audio replay available afterward.
Foundation Medicine announced plans to launch two new germline tests in the United States through a partnership with Fulgent Genetics (NASDAQ: FLGT). The tests, FoundationOne®Germline and FoundationOne®Germline More, will be available from February 28, 2025, and can be added to any Foundation Medicine comprehensive genomic profiling test.
FoundationOne®Germline analyzes 50 genes associated with hereditary cancers, while FoundationOne®Germline More is an expanded panel analyzing 154 genes. Both tests use Fulgent's proprietary technology platform to analyze single nucleotide and copy number variations. When combined with Foundation Medicine's existing tests, they help healthcare providers build comprehensive molecular profiles for cancer patients, explaining cancer development and potential future cancer risks.
Fulgent Genetics (NASDAQ: FLGT) reported Q3 2024 financial results with total revenue of $71.7 million, representing a 9% year-over-year growth in core revenue. The company posted a GAAP loss of $14.6 million (-$0.48 per share) and non-GAAP income of $9.4 million ($0.31 per share). The company maintains strong liquidity with $815.4 million in cash and investments.
Fulgent reiterates its full-year 2024 core revenue guidance of $280 million and improves its GAAP loss guidance from -$1.95 to -$1.70 per share. The company also revised its non-GAAP outlook from a loss of $0.30 per share to an income of $0.33 per share.